In this study, we successfully constructed a novel TriBAFF-CAR-T cell to eliminate BAFFR-bearing and CD19 antigen loss hematological tumor cells both in vitro and in vivo (Fig. 5g). This evidence concerns the gene CD19 and neoplasm.